BMS-935177 is primarily utilized in the field of pharmaceutical research and development. It serves as a potent and selective inhibitor of Bruton's tyrosine kinase (BTK), which plays a crucial role in B-cell signaling pathways. By inhibiting BTK, this compound is investigated for its potential therapeutic applications in treating various B-cell malignancies, such as chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). Additionally, it is studied for its efficacy in managing autoimmune diseases like rheumatoid arthritis, where abnormal B-cell activity contributes to disease progression. Its selective inhibition mechanism makes it a promising candidate for targeted therapies, aiming to minimize off-target effects and improve patient outcomes.